Why Thomas Carls’ Appointment Matters For Alphatec Holdings Stock
Alphatec Holdings (ATEC) brought in Thomas “Tommy” Carls as Executive Vice President of Data Intelligence and Strategy, tasking him with knitting together the company’s imaging, navigation, robotics and analytics platforms.
For context, Alphatec Holdings’ 30-day share price return of 6.46% and 90-day gain of 16.18% sit against a sharp year-to-date share price decline of 51.59% and a 1-year total shareholder return that is down 31.86%. This points to improving short-term momentum after a tougher stretch for longer term holders.
Scan how Alphatec Holdings compares with other spine and medical technology plays by reviewing a curated set of 37 healthcare AI stocks that are leaning into data, robotics, and AI guided procedures.
Alphatec Holdings is pushing hard to build a data rich spine surgery platform, yet the share price is still down sharply over the past year. Is that a strong operating story on sale, or already fairly reflected in today’s US$10.05 quote?
Most Popular Narrative: 37% Undervalued
Against Alphatec Holdings' last close at $10.05, the most followed narrative anchors on a fair value of $16.00, implying a sizable valuation gap that hinges on execution in surgical revenue, margins, and data centric tools like Valence, EOS, and SafeOp.
Expanding surgeon adoption, strong same-store sales growth, and increasing procedural volume signal Alphatec's ability to leverage the aging population and rising prevalence of spinal conditions, driving substantial and durable revenue growth.
Ongoing innovation in integrated procedural solutions and the forthcoming launch of Valence (robotics/navigation) positions the company to capitalize on the accelerating adoption of advanced healthcare technologies, likely boosting both future revenue and long-term margin expansion.
See why 11 investors see Alphatec Holdings as 37% undervalued.
Result: Fair Value of $16.00 (UNDERVALUED)
Still, the Alphatec Holdings story can break if the spine market tilts harder toward non surgical treatments, or if larger rivals squeeze pricing in robotics and data tools.
Find out about the key risks to this Alphatec Holdings narrative.
Next Steps
Feeling the cautious optimism around Alphatec Holdings yet still unsure where you land? Move fast, review the underlying drivers, and weigh the 3 key rewards.
Looking For More Investment Ideas Beyond Alphatec Holdings?
If Alphatec Holdings has your attention, do not stop here. You owe it to your portfolio to compare this story against other focused opportunities right now.
- Target potential mispricing and stack your watchlist with companies that screens flag as compelling using the 32 high quality undervalued stocks.
- Prioritize resilience and stress test your risk tolerance by scanning the 30 resilient stocks with low risk scores for businesses with steadier profiles.
- Hunt for underfollowed stories before they hit the front page by reviewing the 16 high quality undiscovered gems.
This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.
Have feedback on this article? Concerned about the content? Get in touch with us directly. Alternatively, email editorial-team@simplywallst.com